7
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T1995 | Fedratinib | TG-101348,SAR 302503 | Apoptosis , FLT , c-RET , JAK |
Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3. | |||
T9251 | Fedratinib hydrochloride hydrate | TG-101348 hydrochloride hydrate,SAR 302503 hydrochloride hydrate | Apoptosis , JAK |
Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor. | |||
T2638 | Gandotinib | LY2784544 | VEGFR , FGFR , FLT , JAK |
LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM). The selectivity is higher 8- and 20-fold than JAK1 and JAK3. | |||
T6020 | Pacritinib | SB1518 | FLT , Tyrosine Kinases , JAK |
Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays). | |||
T35894 | Atiprimod dihydrochloride | ||
JAK2 inhibitor (IC50 = 397 nM). Also inhibits STAT3 and STAT5 phosphorylation. Inhibits cell growth and induces apoptosis in cells expressing the JAK2V617F mutation. Manshouri et al (2011) Bone marrow stroma-secreted cyt... | |||
T64283 | Pacritinib hydrochloride | ||
Pacritinib hydrochloride is a potent inhibitor of wild-type JAK2 (IC50: 23 nM) and the JAK2V617F mutant (IC50: 19 nM). Pacritinib hydrochloride can be used in the study of acute myeloid leukaemia (AML) and myelofibrosis ... | |||
T73567 | ZT55 | ||
ZT55, an orally active, highly-selective JAK2 inhibitor with an IC50 of 0.031 μM, inhibits proliferation of JAK2 V617F-expressing HEL cell lines, induces apoptosis and cycle arrest, and effectively inhibits HEL xenograft... |